This study investigates a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing cancer. The study tests a drug called [177Lu]Lu-DOTA-TATE along with other drugs: carboplatin, etoposide, and atezolizumab, to see if it's safe and how well it works. The study has three parts: screening, treatment, and follow-up. During screening, doctors check if your cancer has somatostatin receptors (SSTR). Treatment includes an initial phase to find a safe dose and a later phase where participants are randomly assigned to receive the new treatment combination or the standard combination.

• The study lasts several months, including multiple treatment cycles and follow-ups.
• Participants must be at least 18 years old and have not had certain treatments before.
• There may be risks, like side effects from the drugs, and you cannot join if you have other serious health issues.

Before joining, you’ll need to provide a tissue sample and sign a consent form. This study could offer a new hope for treating ES-SCLC, but it’s important to consider the potential risks and time commitment. Consult with your doctor to determine if this study is right for you.